Evicenter
P&T meetings

RP-A501 (AAV9.LAMP2B)

Danon disease

Regulatory submission
BLA planned for late 2028
Last updated
300 sources

Product information and disease descriptionPlace of product in therapyDisease description

Clinical presentation - signs and symptoms

24 evidence topics · 25 sources

Reported clinical characteristics by sex in a registry of 82 participants (percentage of those with data)
CharacteristicMen (n=26)Women (n=18)
Symptomatic heart disease“88.5”“77.7”
Chest pain“41.6”“37.5”
Palpitations“76.5”“68.8”
Hypertrophic cardiomyopathy“88”“33.3”
Dilated cardiomyopathy“12”“27.7”
Conduction abnormality“86.4”“80”
Wolff-Parkinson-White“68.2”“26.7”
Cardiac ablation“53.3”“30.8”
Defibrillator implantation“41.2”“31.3”
Learning and cognitive problems“100”“46.6”
Visual and retinal abnormalities“69.2”“64.2”
Symptomatic muscle disease“80”“50”
Muscle cramping“9.1”“15.3”
Neuropathy“9.1”“38.5”
Symptomatic respiratory disease“50”“16.7”
Symptomatic gastrointestinal disease“76.5”“50”
Cardiac: hypertrophic and dilated phenotypes by sex
Cardiac: pre-excitation and Wolff-Parkinson-White pattern, frequency across cohorts
Cardiac: atrial and ventricular arrhythmias
Skeletal muscle: frequency and distribution of weakness
Skeletal muscle: quantitative strength and timed function tests
Skeletal muscle and hepatic laboratory values in nine males at baseline and follow-up
Neurocognitive: intellectual disability and learning difficulty by sex
Ophthalmic: retinopathy and visual acuity